The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of eribulin on overall survival in patients with metastatic breast cancer with visceral disease.
L. T. Vahdat
Consultant or Advisory Role - Bristol-Myers Squibb (I); Eisai; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; Eisai (I); GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
J. Cortes
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
C. Twelves
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
J. Wanders
Employment or Leadership Position - Eisai
S. Seegobin
Employment or Leadership Position - Eisai
C. Dutcus
Employment or Leadership Position - Eisai
J. O'Shaughnessy
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Eisai; GlaxoSmithKline